Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

Doximity, Inc. (NYSE:DOCS) insider Siddharth Sitaram sold 2,309 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $25.77, for a total transaction of $59,502.93. Following the completion of the transaction, the insider directly owned 89,396 shares in the company, valued at $2,303,734.92. This represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Siddharth Sitaram also recently made the following trade(s):

• On Friday, April 10th, Siddharth Sitaram sold 2,427 shares of Doximity stock. The shares were sold at an average price of $21.09, for a total transaction of $51,185.43.
• On Tuesday, March 10th, Siddharth Sitaram sold 2,319 shares of Doximity stock. The shares were sold at an average price of $25.37, for a total transaction of $58,833.03.

Doximity Trading Down 11.1%

NYSE DOCS opened at $23.52 on Thursday. The company’s 50 day simple moving average is $24.27. Doximity, Inc. has a 52-week low of $20.55 and a 52-week high of $76.51. The company has a market capitalization of $4.34 billion, a P/E ratio of 19.60, a PEG ratio of 1.88 and a beta of 1.36.

Doximity declared that its board has initiated a share buyback plan on Thursday, February 5th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

DOCS has been the topic of a number of recent research reports. Robert W. Baird reiterated a “neutral” rating and set a $18.00 price objective (down from $40.00) on shares of Doximity in a research note on Thursday. Canaccord Genuity Group set a $34.00 price target on shares of Doximity and gave the company a “buy” rating in a report on Monday, February 9th. Needham & Company LLC lowered their price target on shares of Doximity from $55.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday. BTIG Research cut shares of Doximity from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, Bank of America lowered their price target on shares of Doximity from $56.00 to $47.00 and set a “buy” rating on the stock in a report on Thursday, April 16th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.20.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted earnings of $0.26 per share, beating the lower analyst estimate of $0.17, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. Doximity Earnings Report
• Neutral Sentiment: The company’s high margin profile remained intact, with a 23.84% return on equity and 37.54% net margin, suggesting continued operational efficiency. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Despite the earnings beat versus one estimate, Doximity missed the broader Zacks consensus of $0.28 per share, which may have disappointed traders looking for a stronger beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: More importantly for investors, Doximity’s first-quarter FY2027 revenue guidance of $151 million to $152 million came in below the $153.2 million consensus, and full-year FY2027 revenue guidance of $664 million to $676 million also missed the $696 million estimate, signaling a softer outlook. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: The stock also faced added caution from an insider sale earlier in the week, though it was disclosed as part of a pre-arranged 10b5-1 plan and tax withholding related to equity vesting. Insider Trade Disclosure

Institutional Trading of Doximity

A number of institutional investors have recently modified their holdings of DOCS. Royal Bank of Canada boosted its holdings in shares of Doximity by 24.2% in the 1st quarter. Royal Bank of Canada now owns 106,845 shares of the company’s stock valued at $6,200,000 after buying an additional 20,847 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Doximity by 0.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,978 shares of the company’s stock worth $2,262,000 after purchasing an additional 210 shares in the last quarter. NewEdge Advisors LLC boosted its stake in Doximity by 613.7% in the 1st quarter. NewEdge Advisors LLC now owns 6,323 shares of the company’s stock worth $367,000 after purchasing an additional 5,437 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Doximity by 33.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 255,529 shares of the company’s stock worth $14,828,000 after purchasing an additional 63,873 shares in the last quarter. Finally, Focus Partners Wealth acquired a new stake in Doximity in the 1st quarter worth approximately $283,000. 87.19% of the stock is currently owned by institutional investors.

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.